点击上方蓝字关注我们从A股290家医药上市企业的三季报可看出,A股医药行业“马太效应”加剧,行业洗牌正在加速。虽然医药企业整体仍陷于“营收利润双降”的困境,但内部结构已发生转变,企业表现急剧分化。这也标志着中国医药产业正步入一个强者恒强、优胜劣汰的新阶段。290家医药上市企业:2025前三季度减收又减利290家医药上市企业总营收额为7347.68亿元,同比减少5.05%,净利润总额为803.6亿元...
Source Link点击上方蓝字关注我们从A股290家医药上市企业的三季报可看出,A股医药行业“马太效应”加剧,行业洗牌正在加速。虽然医药企业整体仍陷于“营收利润双降”的困境,但内部结构已发生转变,企业表现急剧分化。这也标志着中国医药产业正步入一个强者恒强、优胜劣汰的新阶段。290家医药上市企业:2025前三季度减收又减利290家医药上市企业总营收额为7347.68亿元,同比减少5.05%,净利润总额为803.6亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.